Skip to main content
CG Invites Co., Ltd. logo

CG Invites Co., Ltd. — Investor Relations & Filings

Ticker · 083790 ISIN · KR7083790006 KO Manufacturing
Open in API
Filings indexed 450 across all filing types
Latest filing 2025-01-09 Director's Dealing
Country KR South Korea
Listing KO 083790

About CG Invites Co., Ltd.

https://cginvites.com/en

CG Invites Co., Ltd. is a biopharmaceutical company specializing in digital genomics and personalized medicine. The company's activities are focused on four main areas: genomics, personalized cancer vaccines, digital therapeutics, and the development of chemical and biological drugs. It utilizes Whole Genome Sequencing to support precision medicine initiatives and develops mRNA-based personalized cancer vaccines. The company also creates software-based medical interventions, known as digital therapeutics. Its drug development pipeline includes therapeutics for oncology and inflammatory diseases, such as Acelex for osteoarthritis, Ivaltinostat for pancreatic cancer, and Camrelizumab for immuno-oncology. The company's research approach is based on structural chemoproteomics and the integration of genomic data to develop targeted treatments.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details the acquisition of shares by a major shareholder (Invites Invest) in the company CG Invites. This is a standard regulatory filing in South Korea (DART system) used to report insider or major shareholder transactions, which falls under the 'Director's Dealing' (DIRS) category as it tracks changes in share ownership by significant stakeholders.
2025-01-09 Korean
본점소재지변경
Regulatory Filings Classification · 100% confidence The document is a short, structured announcement regarding a change in the company's headquarters location (본점소재지변경). It does not fit into financial reporting, shareholder voting, or specific corporate action categories like M&A or dividends. As it is a general regulatory announcement regarding corporate administrative changes, it falls under the fallback category for regulatory filings.
2025-01-08 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서), which is a regulatory filing required under the Capital Markets Act in South Korea when an entity or individual acquires a significant stake (typically 5% or more) in a listed company. This document details the shareholding status, changes in ownership, and the purpose of holding (management influence). It fits the definition of a 'Major Shareholding Notification' (MRQ).
2024-12-30 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Major Shareholding Notification Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean financial authorities (Financial Supervisory Service/KRX). This document details the acquisition of shares by a major shareholder (Newlake Invites Investment Co., Ltd.) in the issuing company (CG Invites Co., Ltd.) through market purchases. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) as it tracks changes in significant ownership levels.
2024-12-30 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a short regulatory announcement regarding the setting of a record date for a shareholder meeting (Annual General Meeting). It is a standard corporate disclosure in Korea (DART system) notifying shareholders of the record date for the upcoming AGM. Since it is a regulatory announcement regarding a specific corporate action (setting a record date) rather than the meeting materials themselves or a proxy statement, it falls under the general regulatory filing category.
2024-12-10 Korean
단일판매ㆍ공급계약체결
Regulatory Filings Classification · 100% confidence The document is a formal regulatory filing from a Korean company (CG Invites) announcing the signing of a 'Single Sales/Supply Contract'. It details the contract value, the counterparty (Korea Research Institute of Bioscience and Biotechnology), the contract duration, and the scope of work. Since this is a specific corporate announcement regarding a business contract that does not fit into financial reporting, dividend, or governance categories, it is classified as a general regulatory filing.
2024-12-09 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.